Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients

Oncologist

Volumn 12, Issue 4, 2007, Pages 478-483

  Bennett, Charles L ^a,c   Calhoun, Elizabeth A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Costs; Febrile neutropenia; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMMUNITY HEALTH SERVICES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PILOT PROJECTS; UNITED STATES;

EID: 34247872994     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-4-478     Document Type: Article

References (23)

1. Bennett CL, Lee T. Economic analysis of cancer treatment. In: Abeloff M, Armitage JO, Lichter AS et al. eds. Clinical Oncology. New York: Churchill Livingstone, 2004:395- 405.
2. Bennett CL, Golub R, Calhoun EA et al. Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. Int J Gynecol Cancer 1998;8:64-72.
3. American Cancer Society. Cancer Facts and Figures 2006. Available at http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_Figures_2006.asp. Accessed April 17, 2007.
4. Brown ML, Lipscomb J, Snyder S. The burden of illness of cancer: Economic cost and quality of life. Annu Rev Public Health 2000;22:91-113.
5. Fireman BH, Quesenberry CP, Somkin CP et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997;18:51-76.
6. Souetre E, Qing W. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma. Pharmacoeconomics 1994;6(suppl 2):36-43.
7. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129-146.
8. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection. Support Care Cancer 1997;5:489-499.
9. Calhoun EA, Chang CH, Welshman EE et al. Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients. The Oncologist 2001;6:441-445.
10. Hutton J, Brown R, BorowitzMet al. A new decision model for cost-utility comparisons of chemotherapy in breast cancer. Pharmacoeconomics 1996;9(suppl 2):8-22.
11. Silber JH, Fridman M, Shpilsky A et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16:2435-2444.
12. Hayman JA, Langa KM, Kabeto MU et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol 2001;19:3219-3225.
13. Yabroff KR, Davis WW, Lamont EB et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007;99:14-23.
14. Given BA, Given CW, Stommel M. Family and out-of-pocket costs for women with breast cancer. Cancer Pract 1994;2:187-193.
15. Houts PS, Lipton A, Harvey HA et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy Cancer 1984;53:2388-2392.
16. Arozullah AM, Calhoun EA, WolfMet al. The financial burden of cancer: Estimates from a study of insured women with breast cancer. J Support Oncol 2004;2:271-278.
17. U.S. Department of Commerce Economics and Statistics Administration. Statistical Abstract of the United States 2001. Washington: U.S. Census Bureau. Available at http://www.census.gov/prod/2002pubs/01statab/statab01.html. Accessed March 26, 2007.
18. The Red Book. Montvale, NJ: Medical Economics Company, Inc., 2001:1-856.
19. Talcott JA, Whalen A, Clark J et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-114.
20. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
21. Rubenstein EB, Rolston K, Benjamin RS et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-3646.
22. Rice DP. Cost of illness studies: What is good about them? Inj Prev 2000;6:177-179.
23. Wolf MS, Bennett CL. Local perspective of the impact of the HIPAA privacy rule on research. Cancer 2006;106:474-479.